Myovant Sciences Ltd.


Get free email notifications about news in Myovant Sciences Ltd..

The service is free and you can unsubscribe at any time.

General | People (37) | Filings (83) | Annual reports (1) | Stock | News


CIK Number: 0001679082

Myovant Sciences Ltd. is a publicly traded company

Trading symbol: MYOV



Myovant Sciences secures flexible financing commitments
Times of India
Myovant-Plans to use proceeds to fund ongoing phase 3 development of lead compound relugolix in uterine fibroids, endometriosis & prostate cancer​.


Myovant Sciences Secures Flexible Financing Commitments of up to $140 Million
PR Newswire (press release)
BASEL, Switzerland, Oct. 16, 2017 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV) today announced that it has secured up to $140 million in flexible financing commitments from NovaQuest Capital Management ("NovaQuest") and Hercules Capital, Inc.
Myovant Sciences Ltd (NASDAQ:MYOV) Stock Rating Reaffirmed by Cowen and Company - TrueBlueTribune
Cowen and Company Reiterates “Buy” Rating for Myovant Sciences Ltd (NASDAQ:MYOV) - StockNewsTimes


Tale of the Tape: Myovant Sciences Ltd. (:MYOV) Moves -3.75%
Concord Register
Myovant Sciences Ltd. (:MYOV) shares saw the needle move -3.75% on the week. The stock closed the most recent session at $14.89 after seeing 26781 shares trade hands.
JMP Securities Reaffirms “Outperform” Rating for Myovant Sciences Ltd (MYOV) - StockNewsTimes
What's Behind Myovant Sciences Ltd (MYOV)? Technical Indicators Under Review - Stock Daily Review


Robert W. Baird Reiterates “Buy” Rating for Myovant Sciences Ltd (MYOV)
The Ledger Gazette
Myovant Sciences logo Myovant Sciences Ltd (NASDAQ:MYOV)'s stock had its “buy” rating reiterated by investment analysts at Robert W. Baird in a research report issued on Wednesday.
Myovant Sciences Ltd (MYOV) Holdings Boosted by RA Capital Management LLC - Week Herald
Abaxis, Inc. (ABAX) registers a price change of 0.78% while Myovant Sciences ... - Stocks Gallery


Myovant Sciences: Lead drug succeeds late-stage study in Japan
Times of India
Last year, Roivant Sciences Ltd and Takeda jointly formed Myovant; Takeda gave Myovant worldwide license to develop and market relugolix, except in Japan and some Asian countries where Takeda holds those rights.


Myovant Sciences Ltd. (MYOV) PT Raised to $25 at JMP Securities
JMP Securities analyst Jason Butler raised his price target on Myovant Sciences Ltd. (NYSE: MYOV) to $25.00 (from $23.00) while maintaining a Market Outperform rating as positive Phase 3 results for relugolix in Japan confirm Phase 2 findings and ...
Reversal Time? Myovant Sciences Ltd (MYOV) Schaff Indicator Nearing Key Levels - JCTY News
Myovant Sciences Ltd. (NYSE:MYOV) Moving Today – Up $0.18 - Highlight Press


Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 ...
PR Newswire (press release)
BASEL, Switzerland, Oct. 2, 2017 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV) today announced that Takeda Pharmaceutical Company Limited ("Takeda") has reported positive top-line results from a Phase 3 study evaluating the efficacy and safety of ...
Myovant Sciences Ltd (NASDAQ:MYOV) Upgraded by Zacks Investment Research to Hold - Dispatch Tribunal
Indicator Spotter: Watching the Numbers on Shares of Myovant Sciences Ltd (MYOV) - Hayden Business Journal

Myovant Sciences Ltd. address


Earliest known filing

July 2016

Latest known filing

October 2017

Company filings

SEC filings are a great source of information for companies including investments, company events, and all sorts of other information.

Myovant Sciences Ltd. has 83 filings. View Myovant Sciences Ltd. filings.

Annual Reports

Quarterly Reports

Latest company events


We have found 37 people related to Myovant Sciences Ltd..